Effects of dopamine agonists on the estradiol-induced prolactin surge in ovariectomized female Wistar Han rats
Toxicological Sciences · 2025
DOI: 10.1093/toxsci/kfaf027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Atish Patel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cerevel Therapeutics, LLC, Cambridge, MA 02141, United States. Hauptthemen laut MEDLINE: Prolactin, Ovariectomy, Dopamine Agonists, Estradiol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Cerevel Therapeutics.
Abstract (Originalsprache)
Dopamine agonists (DAs) are approved for the treatment of hypodopaminergic pathologies, including Parkinson’s disease, restless legs syndrome, and periodic limb movement disorder. During drug development, drugs acting on dopaminergic receptors are often associated with a rat-specific endocrine tumor response, including changes in fertility, which are ascribed to DA-induced suppression of pituitary prolactin release. Although these effects are not observed in or relevant to humans, given species differences in the effects of prolactin on reproductive organs, modeling DA-mediated changes in prolactin and the reproductive system remains important for preclinical drug development. We investigated the effects of 2 D2/D3 DAs, pergolide and rotigotine, on the estradiol (E2)-induced prolactin surge in ovariectomized (OVX) female Wistar Han rats. Daily treatment with DAs over 7 days led to a reduction in the prolactin surge in E2-implanted OVX rats. Specifically, pergolide induced a significant decrease in prolactin levels at all time points compared with the OVX-E2 control group. Similarly, rotigotine dose-dependently suppressed plasma prolactin levels compared with the OVX-E2 control group. This study demonstrates the utility of the OVX rat model in evaluating the effects of DAs on the E2-induced prolactin surge. These results support the use of rotigotine, a DA with a long history of safe human use without significant endocrine-related adverse events, as a positive control at a dose level of 5.0 mg/kg/day for future nonclinical toxicity studies investigating the effects of novel DAs on reproductive hormones in rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cerevel Therapeutics, LLC, Cambridge, MA 02141, United States.
- Charles River Laboratories Ashland, LLC, Ashland, OH 44805, United States.
Förderung
- Cerevel Therapeutics
Zitieren
APA
Patel, A., Calkins, T. L., Vidal, J. D., Coder, P. S., Carrier, S., Gokulrangan, G., Chakilam, A. S. R., Akare, S., Briscoe, R. J., & Mondal, M. S. (2025). Effects of dopamine agonists on the estradiol-induced prolactin surge in ovariectomized female Wistar Han rats. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfaf027
Vancouver
Patel A, Calkins TL, Vidal JD, Coder PS, Carrier S, Gokulrangan G, et al. Effects of dopamine agonists on the estradiol-induced prolactin surge in ovariectomized female Wistar Han rats. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfaf027
BibTeX
@article{Patel2025,
author = {Patel, Atish and Calkins, Travis L and Vidal, Justin D and Coder, Pragati S and Carrier, Scott and Gokulrangan, Giri and Chakilam, Ananth Srinivas R and Akare, Sandeep and Briscoe, Richard J and Mondal, Madhu S},
title = {Effects of dopamine agonists on the estradiol-induced prolactin surge in ovariectomized female Wistar Han rats},
journal = {Toxicological Sciences},
year = {2025},
doi = {10.1093/toxsci/kfaf027}
}
EUVIMED